Repositioning Candidate Details
| Candidate ID: | R0343 |
| Source ID: | DB01166 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Cilostazol |
| Synonyms: | |
| Molecular Formula: | C20H27N5O2 |
| SMILES: | O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2 |
| Structure: |
|
| DrugBank Description: | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. |
| CAS Number: | 73963-72-1 |
| Molecular Weight: | 369.4607 |
| DrugBank Indication: | Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest). |
| DrugBank Pharmacology: | Cilostazol reduces the symptoms of intermittent claudication, as indicated by an increased walking distance. Intermittent claudication is pain in the legs that occurs with walking and disappears with rest. The pain occurs due to reduced blood flow to the legs. |
| DrugBank MoA: | Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. |
| Targets: | cGMP-inhibited 3',5'-cyclic phosphodiesterase A |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|